Colgate-Palmolive Co (CL)
Valor JustoFundamental
55
Precio
$84.64
Capitalización Bursátil
$68.97B
Parte 1 · Cuánto vale la empresa
Resumen
Colgate-Palmolive Company, together with its subsidiaries, manufactures and sells consumer products in the United States and internationally. It operates through two segments: Oral, Personal and Home Care; and Pet Nutrition. The Oral, Personal and Home Care segment offers toothpaste, toothbrushes, mouthwash, bar and liquid hand soaps, shower gels, shampoos, conditioners, deodorants and antiperspirants, skin health products, dishwashing detergents, fabric conditioners, household cleaners, and other related items. This segment markets and sells its products under the Colgate, Palmolive, Darlie, elmex, hello, meridol, Sorriso, Tom's of Maine, EltaMD, Filorga, Irish Spring, Lady Speed Stick, PCA SKIN, Protex, Sanex, Softsoap, Speed Stick, Ajax, Axion, Fabuloso, Murphy, Soupline, and Suavitel brands to a range of traditional and eCommerce retailers, wholesalers, and distributors, as well as dentists and skin health professionals. It also offers pharmaceutical products for dentists and other oral health professionals. The Pet Nutrition segment offers pet nutrition products for everyday nutritional needs under the Hill's Science Diet brand; and a range of therapeutic pet products to help nutritionally support dogs and cats in different stages of health under the Hill's Prescription Diet brand; and a fresh pet food sold to pet specialty and other retailers in Australia under Prime100 brand. This segment markets and sells its products through pet supply retailers, veterinarians, and eCommerce retailers. Colgate-Palmolive Company was founded in 1806 and is headquartered in New York, New York.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
Generated on 18 de septiembre de 2026 with claude-haiku-4-5 — shared with all users
P&G sells to the same supermarket shoppers in nearly every Colgate category, with Crest and Oral-B against Colgate toothpaste and toothbrushes, Olay and Old Spice against Palmolive and Softsoap, and Dawn and Tide against Colgate's home-care lines.
Church & Dwight targets the same US household shopper with TheraBreath mouthwash and Arm & Hammer toothpaste against Colgate's oral care, and with Arm & Hammer and OxiClean against its cleaning brands.
Unilever fights Colgate for the same shelf space in oral care (Closeup, Pepsodent) and personal care (Dove, Lifebuoy), above all in the emerging markets that generate a large share of Colgate's sales.
Haleon is the main rival in premium therapeutic oral care, where Sensodyne, Parodontax and Polident compete directly with Colgate Sensitive, Colgate Total and Colgate's denture-care products, often on pharmacist and dentist recommendation.
Through Purina and Purina Pro Plan Veterinary Diets, Nestlé is the largest player in the pet food aisles and veterinary clinics where Colgate's Hill's Science Diet and Prescription Diet earn roughly a quarter of group sales.
Reckitt competes for the same home-care and hygiene budget, with Lysol, Finish and Air Wick facing Colgate's Ajax, Fabuloso, Axion and Suavitel across the US, Europe and Latin America.
Balance y Liquidez
Ingresos
$21.05B
Últimos 12 meses (hasta 30/6/2026)
Beneficio Neto
$2.04B
Últimos 12 meses (hasta 30/6/2026)
Flujo de Caja Libre
$3.63B
Patrimonio Neto Total
$54M
Pasivo Total
$15.96B
Ratio de Liquidez
1.03
Cobertura de Intereses
12.32
Deuda/EBITDA
1.99
Beneficio Por Acción
Ingresos y Beneficio Neto
Flujo de Caja Libre
Desglose de Ingresos
Estado histórico
Márgenes en el tiempo
La deuda en el tiempo
Cuánto pesa la deuda
Cuadro de crecimiento
Crecimiento — Ingresos
Estimación de Valor Justo
Valor Justo
$71.98
Precio Actual
$84.64
Margen de Seguridad
-17.6%
Rango de Valor Justo
$46.79 - $97.17
Dispersión entre los métodos de valoración utilizados, no un intervalo de confianza calibrado estadísticamente.
Métodos de Estimación
Métricas de Valoración
Ratio P/E
33.72
ROE
3948.1%
Ratio P/B
288.20
P/FCF
17.63
Margen Bruto
60.4%
ROIC
23.2%
Radar de Rentabilidad
Creación de Valor (Ventaja Competitiva)
ROIC
23.2%
WACC
7.5%
ROIC − WACC
+15.8 pp
El ROIC supera el coste del capital: la empresa está creando valor para los accionistas.
Criterios de Análisis Fundamental
Superado (14)
- ROIC 23.2%
- Gross Margin 60.4%
- P/FCF 17.63
- Operating Margin 14.9%
- Positive Free Cash Flow
- CapEx intensity
- Current Ratio
- Interest Coverage
- Debt/EBITDA
- Return on Tangible Assets
- ROE 631.1%
- Analyst Consensus 65% Buy
- Earnings Quality (OCF/NI) 2.19
- Share Dilution -1.5%
Fallido (12)
- EPS shows upward trend
- EPS CAGR -1.08%
- Price CAGR 2.87%
- P/B Ratio 288.20
- Debt/Equity ratio
- Low reliance on intangibles
- Price below Graham Number
- DCF valuation (Overvalued)
- Revenue Growth 5Y 4.3%
- Earnings Surprise avg 0.4%
- Net Margin Trend 9.7% vs 14.5%
- Piotroski F-Score 4/9
No disponible (2)
- Dividend Payout NaN%
- PEG Ratio (need PE > 0 and growth > 0)
Piotroski F-Score
Señales mixtas: algunas áreas requieren atención
Calidad de los Beneficios
Alta calidad: beneficios respaldados por efectivo
Dilución de Acciones
Recomprando acciones. Favorable para el accionista
Participaciones institucionales
Gobernanza
Equipo Directivo
| Nombre | Cargo | Edad |
|---|---|---|
| Mr. Noel R. Wallace | Chairman, CEO & President | 61 |
| Mr. Stanley J. Sutula III | Chief Financial Officer | 59 |
| Mr. Panagiotis Tsourapas | COO of Global Customer Dev., Europe Middle East Africa, Asia Pacific & Global Skin Health | 60 |
| Mr. Shane Grant | Chief Operating Officer of Americas | 50 |
| Mr. Stephan Habif | Chief Technology Officer | - |
| Mr. David Foster | Chief Information Officer | - |
| Mr. John Faucher | Chief Investor Relations Officer and Executive VP of M&A | - |
| Ms. Betsy Fishbone | EVP, Chief Legal Officer & Secretary | - |
| Mr. Eutychus Karuru | Executive Vice President of Internal Audit & Compliance | - |
| Mr. Dana Bolden | Chief Communications Officer | 57 |
Riesgo de Auditoría
3
Riesgo del Consejo
5
Riesgo de Compensación
4
Riesgo de Derechos del Accionista
2
Parte 2 · El precio y el momento de entrar
Esta parte no sirve para saber si la empresa vale: sirve para elegir cuándo comprarla, una vez que los fundamentales te han convencido. Dentro: análisis técnico, potencial, caídas históricas, exposición gamma.
Documentos
- Ver documento
Informe anual (10-K)
Un resumen anual del negocio, los resultados financieros y los riesgos de la empresa.
Presentado el 2026-02-23
- Ver documento
Informe trimestral (10-Q)
Una actualización del desempeño financiero de los últimos tres meses.
Presentado el 2026-07-31
- Ver documento
Informe de hecho relevante (8-K)
Un aviso sobre un hecho relevante, como un cambio de dirección o un anuncio importante.
Presentado el 2026-07-31
via SEC EDGAR
Historial de Resultados
via SEC EDGAR
Latest News
Recent headlines for CL, sourced from Markets Gazette.